Editas Medicine (NASDAQ:EDIT) on Friday announced initial safety and efficacy data from a pair of trials designed to evaluate EDIT-301, a gene editing candidate targeted at inherited blood disorders, ...
Editas Medicine presents preclinical data on gene editing at ASGCT, aiming to develop candidates for hematopoietic and liver therapies by 2025. Editas Medicine, Inc. announced its progress in the ...
Editas Medicine may have been first to enter the clinic with a gene-editing therapy, but it was beaten to the finish line by Intellia with first-in-human results in June. But it’s not a competition.
CRISPR’s use has vast potential in basic research to add to the understanding of cellular activity and in healthcare for precision therapies for today’s untreatable diseases. To date, some 30 clinical ...
WALTHAM, Mass. & DURHAM, N.C.--(BUSINESS WIRE)--Life Edit ® Therapeutics Inc., an ElevateBio ® company focused on next-generation gene editing technologies and therapeutics, today announced the ...
CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology Company committed to delivering a new class of differentiated, one-time curative genetic ...
Robust efficacy data: ≥90% LDL-C reduction in non-human primates achieved within 48 hours of a single dose of EDIT-401; ≥90% LDL-C reduction in mice with high baseline LDL-C and reduced LDLR function ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results